Drummond announced today that ThinkBio.Ai®, Inc., a pioneer in AI-powered translational research solutions, has successfully achieved the pDSI-Risk Certification for predictive decision support interventions (pDSI) in health care.
This milestone validates that ThinkBio’s AI platform integrates essential safeguards for Intervention Risk Management (IRM) and end-user understanding from documented Source Attributes, aligning with ASTP/ONC standards for AI-enabled tools supporting healthcare organizations.
This new certification program assesses whether AI technologies can responsibly identify and mitigate risks, explain the origins of their recommendations, and disclose governance practices in ways that are accessible and trustworthy to end users. ThinkBio demonstrated its capabilities across real-world research and clinical scenarios, with a strong emphasis on transparency, traceability, and responsible management of AI in sensitive healthcare contexts.
“AI has the potential to accelerate discovery and improve care, but it must be delivered in a way that researchers and clinicians can fully trust,” said Mr. Pradeep Palazhi, Founder and CEO, ThinkBio.Ai®. “This certification affirms our belief that accountability and transparency are not optional, they are foundational to every solution we bring to the clinical research ecosystem,” he added.
“ThinkBio’s solution illustrates how governance can be built into AI workflows from the start,” said John Valutkevich, Director of Programs at Drummond. “They have shown that it is possible to combine scientific innovation with structured safeguards, creating tools that are both cutting-edge and responsibly managed,” he added.
Drummond’s pDSI-Risk Certification program provides a pathway for AI developers, EHR vendors, and health IT innovators to demonstrate their products meet rising expectations for transparency, accountability, and AI risk governance.
For ThinkBio.Ai®, this achievement not only validates its technical capabilities but also signals its readiness to serve the healthcare market, where assurance, trust, and compliance are critical factors for adoption.
By achieving the certification, ThinkBio.Ai® reinforces its commitment to ensuring that AI remains a trustworthy partner in clinical decision-making and research advancement. The certification positions the company to expand its role in bridging discovery and care, helping health systems and research organizations adopt AI with confidence.
Read the original press release